Fig. 2
Timeline of anemia, transfusion and interventions. The patient was transfusion dependent for the management of his normocytic hypoproliferative anemia between November 2019 and May 2020. His olaparib and pembrolizumab given for the management of his prostate cancer was stopped in December 2019. A bone marrow biopsy in February 2020 revealed evidence of lymphoplasmacytic lymphoma with a Myd88 mutation. His serum protein electrophoresis was notable for an IgM monoclonal protein. He was started on bendamustine (90 mg/m2 on days 1 and 2) and rituximab (500 mg/m2 on day 1) for 6 cycles. He was soon transfusion independent and repeat bone marrow biopsy on completion of bendamustine and rituximab demonstrated a complete response. Hb hemoglobin, Ig immunoglobulin